Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well-defined.
Chen and colleagues report that a T878A androgen receptor mutation occurs in subset of patients progressing while receiving abiraterone, suggesting this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer (CRPC).
Sharifi N. Are you the author?
Cancer Biology, Cleveland Clinic.
Reference: Clin Cancer Res. 2014 Nov 28. pii: clincanres.2899.2014.